These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9139833)

  • 1. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
    Jäger E; Ringhoffer M; Altmannsberger M; Arand M; Karbach J; Jäger D; Oesch F; Knuth A
    Int J Cancer; 1997 Apr; 71(2):142-7. PubMed ID: 9139833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
    Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
    Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
    J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients.
    Kageshita T; Kawakami Y; Ono T
    J Dermatol Sci; 2001 Jan; 25(1):36-44. PubMed ID: 11154862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals.
    Jäger E; Ringhoffer M; Arand M; Karbach J; Jäger D; Ilsemann C; Hagedorn M; Oesch F; Knuth A
    Melanoma Res; 1996 Dec; 6(6):419-25. PubMed ID: 9013479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response.
    Milani V; Frankenberger B; Heinz O; Brandl A; Ruhland S; Issels RD; Noessner E
    Int Immunol; 2005 Mar; 17(3):257-68. PubMed ID: 15642953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
    Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
    Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
    Michaeli Y; Denkberg G; Sinik K; Lantzy L; Chih-Sheng C; Beauverd C; Ziv T; Romero P; Reiter Y
    J Immunol; 2009 May; 182(10):6328-41. PubMed ID: 19414786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.
    Mendez R; Serrano A; Jäger E; Maleno I; Ruiz-Cabello F; Knuth A; Garrido F
    Tissue Antigens; 2001 Jun; 57(6):508-19. PubMed ID: 11556981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
    Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
    Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
    Khong HT; Wang QJ; Rosenberg SA
    J Immunother; 2004; 27(3):184-90. PubMed ID: 15076135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.
    Reinke S; Königer P; Herberth G; Audring H; Wang H; Ma J; Guo Y; Sterry W; Trefzer U
    Am J Dermatopathol; 2005 Oct; 27(5):401-6. PubMed ID: 16148409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma.
    Hofbauer GF; Burkhart A; Schüler G; Dummer R; Burg G; Nestle FO
    J Immunother; 2004; 27(1):73-8. PubMed ID: 14676635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
    de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
    Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.